On 2014 Jul 30, Jim Woodgett commented:

From the data published, this compound was not tested against GSK-3alpha. Given the virtual identity in the active (ATP binding) site of these two isoforms, it is extremely probable that 6-(4-Pyridyl)pyrimidin-4(3H)-ones also inhibit GSK-3alpha (and are not specific for GSK-3beta). Notably, this molecule appears to pass through the blood brain barrier unlike many other inhibitors to this kinase providing avenues for targeting this kinase in Alzheimers and other neuropsychiatric conditions.

On 2014 Jul 30, Jim Woodgett commented:

From the data published, this compound was not tested against GSK-3alpha. Given the virtual identity in the active (ATP binding) site of these two isoforms, it is extremely probable that 6-(4-Pyridyl)pyrimidin-4(3H)-ones also inhibit GSK-3alpha (and are not specific for GSK-3beta). Notably, this molecule appears to pass through the blood brain barrier unlike many other inhibitors to this kinase providing avenues for targeting this kinase in Alzheimers and other neuropsychiatric conditions.